S116: LONG-TERM EFFICACY AND SAFETY OF THE ORAL PYRUVATE KINASE ACTIVATOR MITAPIVAT IN ADULTS WITH NON—TRANSFUSION-DEPENDENT ALPHA- OR BETA-THALASSEMIA
Kevin H.M. Kuo(University Health Network), Elliott Vichinsky(Unknown), Joy Bhatia(Agios Pharmaceuticals (United States)), Penelope A. Kosinski(Agios Pharmaceuticals (United States)), Bo Tong(AbbVie (United States)), Hanny Al‐Samkari(Harvard University), K Uhlig(Tufts University), Ashutosh Lal(Post Graduate Institute of Medical Education and Research), D. Mark Layton(Imperial College Healthcare NHS Trust), Megan T. Lynch(University of Maryland, Baltimore)
Cited by 1
Related Papers
Sickle cell disease
|Nature Reviews Disease Primers|2018|1.4k
A Phase 3 Trial of Luspatercept in Patients with Transfusion-Dependent β-Thalassemia
|New England Journal of Medicine|2020|320
Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study
|Blood|2018|165
Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency
|New England Journal of Medicine|2019|162
Thrombosis, Bleeding, and the Observational Effect of Early Therapeutic Anticoagulation on Survival in Critically Ill Patients With COVID-19
|Annals of Internal Medicine|2021|140